Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine, and pimozide
- PMID: 2428411
- DOI: 10.1016/0006-3223(86)90219-2
Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine, and pimozide
Abstract
Chronic administration of the neuroleptic haloperidol, the calcium channel antagonist nitrendipine, and the calcium channel antagonist neuroleptic pimozide produce differential effects on rat striatal 3H-spiperone binding. Following 7 days of 10 mg/kg i.p. administration, haloperidol significantly increases (p less than 0.01) dopamine D2 receptor binding to 123% +/- 6% of control values, whereas pimozide treatment significantly reduces (p less than 0.001) striatal 3H-spiperone binding to 46% +/- 6% of control values. Chronic administration of the calcium channel antagonist nitrendipine does not alter 3H-spiperone binding relative to control values. Saturation analysis reveals an increase in Bmax following chronic haloperidol and a decrease in Bmax following chronic pimozide treatment. No alterations in muscarinic cholinergic sites, dopamine uptake sites, or calcium channel antagonist sites result following chronic drug administration. These results are the first demonstration of a decrease in dopamine D2 binding sites after chronic neuroleptic treatment.
Similar articles
-
Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain.Brain Res. 1989 May 22;487(2):288-98. doi: 10.1016/0006-8993(89)90833-0. Brain Res. 1989. PMID: 2525063
-
Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade.Brain Res. 1987 Dec 1;435(1-2):147-52. doi: 10.1016/0006-8993(87)91595-2. Brain Res. 1987. PMID: 2962698
-
Dopamine D2 receptors in the striatum and frontal cortex following chronic administration of haloperidol.Neuropharmacology. 1987 May;26(5):481-3. doi: 10.1016/0028-3908(87)90031-1. Neuropharmacology. 1987. PMID: 2955242
-
Chronic haloperidol does not alter agonist affinity for dopamine receptors in vitro.Eur J Pharmacol. 1985 Mar 12;109(3):389-94. doi: 10.1016/0014-2999(85)90400-5. Eur J Pharmacol. 1985. PMID: 3157587
-
Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats.Psychopharmacology Suppl. 1985;2:174-81. doi: 10.1007/978-3-642-70140-5_21. Psychopharmacology Suppl. 1985. PMID: 3159009
Cited by
-
Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine.J Psychiatry Neurosci. 1999 May;24(3):248-9. J Psychiatry Neurosci. 1999. PMID: 10354660 Free PMC article. No abstract available.
-
Behavioural tests of the dopamine depletion hypothesis of neuroleptic-induced response decrement.Psychopharmacology (Berl). 1992;106(4):543-9. doi: 10.1007/BF02244828. Psychopharmacology (Berl). 1992. PMID: 1349755
-
Effects of chronic haloperidol on stress-induced oral behaviour in rats.Psychopharmacology (Berl). 1989;98(4):476-82. doi: 10.1007/BF00441945. Psychopharmacology (Berl). 1989. PMID: 2505287
-
Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy.Neuropsychopharmacology. 2011 May;36(6):1289-95. doi: 10.1038/npp.2011.14. Epub 2011 Feb 23. Neuropsychopharmacology. 2011. PMID: 21346734 Free PMC article. Clinical Trial.
-
The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer.Oncotarget. 2018 Oct 9;9(79):34889-34910. doi: 10.18632/oncotarget.26175. eCollection 2018 Oct 9. Oncotarget. 2018. PMID: 30405882 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
